Empagliflozin to preserve kidney function in new peritoneal dialysis patients
Treatments studied
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have started peritoneal dialysis (PD) within the past 3 months and still have a Tenckhoff catheter in place.
- You are between 18 and 75 years old.
- You may or may not have type 2 diabetes.
- Your kidneys still make at least 400 ml of urine per day, and your remaining kidney function is above a certain level.
- You have not taken any SGLT2 inhibitors (like empagliflozin, dapagliflozin, or canagliflozin) in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
Hear when a new End Stage Renal Disease on Dialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.